{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:53:54Z","timestamp":1791176034161,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>SMARCA4-deficient non-small cell lung cancer (SD-NSCLC) is a highly aggressive molecular subtype. This malignancy is often diagnosed at an advanced stage, carrying a dismal prognosis and also demonstrating poor responsiveness to traditional treatment. Beyond its primary site, the disease can exhibit unusual metastatic patterns such as metastasis to oral soft tissues. We report a unique case of a 61-year-old male heavy smoker with molecularly confirmed SD-NSCLC who experienced rapid metastatic progression to the right gingiva and neck lymph nodes shortly after radical surgery and initial chemo-immunotherapy. This clinical scenario exemplifies primary resistance to immune checkpoint inhibitors (ICIs), where pre-existing genetic or microenvironmental barriers hinder initial therapeutic success. To overcome this resistance, a salvage multimodal strategy was implemented, integrating ICIs with etoposide\/cisplatin (EP) chemotherapy and low-dose radiotherapy (LDRT). Remarkably, this regimen achieved significant regression of the bulky metastatic lesions and has maintained sustained disease stability for over 15 months, with the patient remaining clinically stable as of the latest follow-up in June 2026. This case may hint the potential role of LDRT as an immunomodulatory component to overcome primary resistance in SD-NSCLC, suggesting a potential therapeutic strategy for patients who experience disease progression following first-line chemo-immunotherapy.<\/jats:p>","DOI":"10.3389\/fonc.2026.1941008","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:32:44Z","timestamp":1791174764000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Low-dose radiotherapy as part of multimodal salvage therapy for immunotherapy-resistant SMARCA4-deficient non\u2010small cell lung cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Tong","family":"Bu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research","place":["Nanjing, China"]},{"name":"Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research","place":["Nanjing, China"]},{"name":"Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research","place":["Nanjing, China"]},{"name":"Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research","place":["Nanjing, China"]},{"name":"Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research","place":["Nanjing, China"]},{"name":"Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research","place":["Nanjing, China"]},{"name":"Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research","place":["Nanjing, China"]},{"name":"Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research","place":["Nanjing, China"]},{"name":"Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1825","article-title":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6083","article-title":"Clinical characteristics and prognostic analysis of SMARCA4\u2010deficient non\u2010small cell lung cancer","volume":"12","author":"Liang","year":"2023","journal-title":"Cancer Med"},{"key":"B3","unstructured":"A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.05.020","article-title":"LEAP-008: Lenvatinib plus pembrolizumab for metastatic NSCLC that has progressed after an anti-programmed cell death protein 1 or anti-programmed cell death ligand 1 plus platinum chemotherapy","volume":"20","author":"Leighl","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"35","author":"Borghaei","year":"2024","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02166","article-title":"CONTACT-01: A randomized phase III trial of atezolizumab + cabozantinib versus docetaxel for metastatic non-small cell lung cancer after a checkpoint inhibitor and chemotherapy","volume":"42","author":"Neal","year":"2024","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2026.116583","article-title":"Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project","volume":"245","author":"Molina-Vila","year":"2026","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: Challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108891","article-title":"Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials","volume":"212","author":"Zhou","year":"2026","journal-title":"Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105353","article-title":"Overcoming conditional immune resistance in MSS and pMMR colorectal cancer: A sequential gating framework for immunotherapy","volume":"223","author":"Farah","year":"2026","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107255","article-title":"Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study","volume":"181","author":"Tian","year":"2023","journal-title":"Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012288","article-title":"Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: The role of KEAP1, SMARCA4, and PTEN mutations","volume":"13","author":"Paredes","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101215","article-title":"Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs","volume":"81","author":"Dong","year":"2025","journal-title":"Drug Resistance Updates"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102665","article-title":"Sex- and co-mutation-dependent prognosis in patients with SMARCA4-mutated malignancies","volume":"15","author":"Pan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00903-x","article-title":"Radiation as an immune modulator: Mechanisms and implications for combination with immunotherapy","volume":"26","author":"Darragh","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B24","unstructured":"A phase 1 open-label, multi-center, safety and efficacy study of PRT3789 as monotherapy and in combination with docetaxel in participants with advanced or metastatic solid tumors with a SMARCA4 mutation\n          \n          \n          Clinicaltrials.Gov\n          \n          2025"},{"key":"B25","unstructured":"A phase 1 open-label, multi-center, safety and efficacy study of PRT7732, an oral SMARCA2 degrader, in patients with advanced or metastatic solid tumors with a SMARCA4\n          \n          \n          Clinicaltrials.Gov\n          \n          2026"},{"key":"B26","unstructured":"A phase 2, safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors with a SMARCA4 mutation\n          \n          \n          Clinicaltrials.Gov\n          \n          2026"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0315","article-title":"Safety and tolerability of low-dose radiation and stereotactic body radiotherapy + sintilimab for treatment-na\u00efve stage IV PD-L1+ non-small cell lung cancer patients","volume":"29","author":"Zhou","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B28","unstructured":"SMARCA4-deficient undifferentiated gastric cancer: A case report and review of the literature\n          \n          \n            \n              Bhatt\n              P\n            \n            \n              Kothari\n              R\n            \n            \n              Modi\n              G"},{"key":"B29","unstructured":"Frontiers | Case report: Recognition and management of SMARCA4-deficient renal cell carcinoma"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1941008\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:33:10Z","timestamp":1791174790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1941008\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":29,"alternative-id":["10.3389\/fonc.2026.1941008"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1941008","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1941008"}}